Quick Answer
ZIMMER BIOMET HOLDINGS, INC. reported Total Revenue of $8.23 billion for fiscal year 2025.
ZIMMER BIOMET HOLDINGS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $8.23B +7.2% |
$7.68B +3.8% |
$7.39B +6.5% |
$6.94B +1.6% |
$6.83B +11.4% |
$6.13B -23.2% |
| Revenue (ASC 606) | $8.23B +7.2% |
$7.68B +3.8% |
$7.39B +6.5% |
$6.94B +1.6% |
$6.83B +11.4% |
$6.13B -23.2% |
| Net Income | $705.10M -22.0% |
$903.80M -11.7% |
$1.02B +342.5% |
$231.40M -42.4% |
$401.60M +389.1% |
-$138.90M -112.3% |
| Diluted EPS | $3.55 -19.9% |
$4.43 -9.2% |
$4.88 +343.6% |
$1.10 -42.4% |
$1.91 +385.1% |
-$0.67 -112.2% |
| Total Assets | $23.09B +8.1% |
$21.37B -0.6% |
$21.50B +2.0% |
$21.07B -10.2% |
$23.46B -3.9% |
$24.42B -0.9% |
| Cash and Equivalents | $591.90M +12.6% |
$525.50M +26.4% |
$415.80M +10.7% |
$375.70M -0.6% |
$378.10M -52.9% |
$802.10M +29.8% |
| Long-Term Debt | $6.93B +29.8% |
$5.34B +9.7% |
$4.87B -5.5% |
$5.15B -5.7% |
$5.46B -28.4% |
$7.63B +13.5% |
| Stockholders Equity | $12.70B +1.8% |
$12.47B -0.1% |
$12.48B +3.8% |
$12.02B -5.1% |
$12.66B +3.8% |
$12.19B -1.6% |
| R&D Expense | — | — | — | — | — | — |
| Operating Income | $1.10B -14.6% |
$1.29B +0.6% |
$1.28B +83.5% |
$696.30M -19.1% |
$860.30M +935.3% |
$83.10M -92.7% |
| Gross Profit | — | — | — | — | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $2.00B | +9.7% | -3.7% |
| Revenue (ASC 606) | September 30, 2025 | $2.00B | +9.7% | -3.7% |
| Net Income | September 30, 2025 | $230.90M | -7.3% | +51.1% |
| Diluted EPS | September 30, 2025 | $1.16 | -5.7% | +50.6% |
| Total Assets | September 30, 2025 | $23.49B | +8.1% | +2.7% |
| Cash and Equivalents | September 30, 2025 | $1.29B | +127.2% | +132.1% |
| Long-Term Debt | September 30, 2025 | $7.51B | +58.6% | +11.3% |
| Stockholders Equity | September 30, 2025 | $12.76B | +3.1% | +1.8% |
| R&D Expense | March 31, 2013 | $53.50M | -10.2% | +0.0% |
| Operating Income | September 30, 2025 | $351.30M | +25.7% | +17.1% |
| Gross Profit | June 30, 2015 | $877.10M | +3.0% | +2.5% |
- ZIMMER BIOMET HOLDINGS, INC. reported Total Revenue of $8.23 billion for fiscal year 2025.
- ZIMMER BIOMET HOLDINGS, INC. showed an increase of +7.2% in Total Revenue compared to the prior fiscal year.
- ZIMMER BIOMET HOLDINGS, INC. reported Revenue (ASC 606) of $8.23 billion for fiscal year 2025.
- ZIMMER BIOMET HOLDINGS, INC. showed an increase of +7.2% in Revenue (ASC 606) compared to the prior fiscal year.
- ZIMMER BIOMET HOLDINGS, INC. reported Net Income of $705.10 million for fiscal year 2025.
- ZIMMER BIOMET HOLDINGS, INC. showed a decrease of -22.0% in Net Income compared to the prior fiscal year.
- ZIMMER BIOMET HOLDINGS, INC. reported Diluted EPS of $3.55 per share for fiscal year 2025.
- ZIMMER BIOMET HOLDINGS, INC. showed a decrease of -19.9% in Diluted EPS compared to the prior fiscal year.
- ZIMMER BIOMET HOLDINGS, INC. reported Total Assets of $23.09 billion for fiscal year 2025.
- ZIMMER BIOMET HOLDINGS, INC. showed an increase of +8.1% in Total Assets compared to the prior fiscal year.
- ZIMMER BIOMET HOLDINGS, INC. reported Cash and Equivalents of $591.90 million for fiscal year 2025.
- ZIMMER BIOMET HOLDINGS, INC. showed an increase of +12.6% in Cash and Equivalents compared to the prior fiscal year.
- ZIMMER BIOMET HOLDINGS, INC. reported Long-Term Debt of $6.93 billion for fiscal year 2025.
- ZIMMER BIOMET HOLDINGS, INC. showed an increase of +29.8% in Long-Term Debt compared to the prior fiscal year.
- ZIMMER BIOMET HOLDINGS, INC. reported Stockholders Equity of $12.70 billion for fiscal year 2025.
- ZIMMER BIOMET HOLDINGS, INC. showed an increase of +1.8% in Stockholders Equity compared to the prior fiscal year.
- ZIMMER BIOMET HOLDINGS, INC. reported R&D Expense of $225.60 million for fiscal year 2012.
- ZIMMER BIOMET HOLDINGS, INC. showed a decrease of -5.4% in R&D Expense compared to the prior fiscal year.
- ZIMMER BIOMET HOLDINGS, INC. reported Operating Income of $1.10 billion for fiscal year 2025.
- ZIMMER BIOMET HOLDINGS, INC. showed a decrease of -14.6% in Operating Income compared to the prior fiscal year.
- ZIMMER BIOMET HOLDINGS, INC. reported Gross Profit of $3.42 billion for fiscal year 2014.
- ZIMMER BIOMET HOLDINGS, INC. showed an increase of +2.6% in Gross Profit compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: